Ranchi News Desk

Pancreatic Cancer Clinical and Non-Clinical Studies, Key Companies, Therapeutic Assessment, Emerging Therapies, Treatment Algorithm, and Pipeline Analysis

 Breaking News
  • No posts were found

Pancreatic Cancer Clinical and Non-Clinical Studies, Key Companies, Therapeutic Assessment, Emerging Therapies, Treatment Algorithm, and Pipeline Analysis

July 01
20:08 2021
Pancreatic Cancer Clinical and Non-Clinical Studies, Key Companies, Therapeutic Assessment, Emerging Therapies, Treatment Algorithm, and Pipeline Analysis

DelveInsight Business Research LLP
DelveInsight’s, “Pancreatic Cancer – Pipeline Insight, 2021,” report provides comprehensive insights about 100+ companies and 100+ pipeline drugs in the Pancreatic Cancer pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Pancreatic Cancer Pipeline Insight, 2021” report by DelveInsight outlines comprehensive insights of present clinical development scenario and growth prospects across the Pancreatic Cancer Market.

The assessment part of the report embraces in-depth Pancreatic Cancer commercial assessment and clinical assessment of the Pancreatic Cancer pipeline products from the pre-clinical developmental phase to the marketed phase.

In the report, a detailed description of the drug is proffered including mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Pancreatic Cancer collaborations, licensing mergers, and acquisition, funding, designations, and other product-related details.

Get FREE sample copy at: https://www.delveinsight.com/sample-request/pancreatic-cancer-pipeline-insight

Pancreatic Cancer Overview

Pancreatic adenocarcinoma is one of the most aggressive forms of cancer and is projected to arise as the second leading cause of cancer-related deaths in Europe and the United States shortly. In the US, pancreatic cancer is the 9th or 10th  most commonly diagnosed cancer (depending on gender).

A clinical/radiographic stage classification for pancreatic cancer suggests a three-stage classification (potentially resectable, locally advanced, and advanced) of pancreatic cancer involvement based on radiological findings.

Pancreatic Cancer Emerging Therapy Assessment:

Apart from the already existing players such as OSI Pharmaceuticals and Eli Lily along with others, there are several emerging key players, which are expected to change the dynamics of the Pancreatic Cancer market in the coming years owing to the positive outcomes of the emerging pipeline candidates, which includes FibroGen (Pamrevlumab), SynCore Biotechnology (EndoTAG-1), AB Science (Masitinib), AstraZeneca (AZD6738), NanOlogy (NanoPac), NantKwest/ ImmunityBio (PD-L1 t-hank and N-803), Rafael Pharmaceuticals (CPI-613), Galera Therapeutics (GC4419) along with several others that are under clinical development. The launch of these emerging therapies is expected during the forecast period of 2021–2030.

Pancreatic Cancer Key Companies:

  1. FibroGen

  2. SynCore Biotechnology

  3. Galera Therapeutics 

  4. Singh Biotechnology

  5. AB Science

  6. AstraZeneca 

  7. NanOlogy

  8. NantKwest/ImmunityBio

  9. Rafael Pharmaceuticals 

Pancreatic Cancer Therapies covered in the report include:

  1. Pamrevlumab (Anti CTGF antibody) 

  2. EndoTAG-1 (ET)

  3. GC4419

  4. SBT-100

  5. Masitinib

  6. AZD6738 

  7. NanoPac

  8. PD-L1 t-hank and N-803

  9. CPI-613 (devimistat)

Report Highlights:

  1. A better understanding of disease pathogenesis contributing to the development of novel therapeutics for Pancreatic Cancer.

  2. In the coming years, the Pancreatic Cancer market is set to change due to the rising awareness of the disease and incremental healthcare spending across the world, expanding the size of the market to enable the drug manufacturers to penetrate more into the market.

  3. The companies and academics are working to assess challenges and seek opportunities that could influence Pancreatic Cancer Research & Development. The therapies under development are focused on novel approaches to treat/improve the disease condition.

  4. A detailed portfolio of major pharma players who are involved in fueling the Pancreatic Cancer treatment market. Several potential therapies for Pancreatic Cancer are under investigation. With the expected launch of these emerging therapies, it is expected that there will be a significant impact on the Pancreatic Cancer market size in the coming years. 

  5. Our in-depth analysis of the Pancreatic Cancer pipeline assets (in early-stage, mid-stage, and late stage of development) includes therapeutic assessment and comparative analysis. This will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities.

Get FREE sample copy at: https://www.delveinsight.com/sample-request/pancreatic-cancer-pipeline-insight

Table of Contents

  1. Report Introduction

  2. Pancreatic Cancer

  3. Pancreatic Cancer Current Treatment Patterns

  4. Pancreatic Cancer – DelveInsight’s Analytical Perspective

  5. Therapeutic Assessment

  6. Pancreatic Cancer Late Stage Products (Phase-III)

  7. Pancreatic Cancer Mid Stage Products (Phase-II)

  8. Early Stage Products (Phase-I)

  9. Pre-clinical Products and Discovery Stage Products

  10. Inactive Products

  11. Dormant Products

  12. Pancreatic Cancer Discontinued Products

  13. Pancreatic Cancer Product Profiles

  14. Pancreatic Cancer Key Companies

  15. Pancreatic Cancer Key Products

  16. Dormant and Discontinued Products

  17. Pancreatic Cancer Unmet Needs

  18. Pancreatic Cancer Future Perspectives

  19. Pancreatic Cancer Analyst Review 

  20. Appendix

  21. Report Methodology

*The table of contents is not exhaustive; the final content may vary.

Related Reports: 

Pancreatic Cancer Market

DelveInsight’s “Pancreatic Cancer Market Insights, Epidemiology and Market Forecast – 2030” report provides a detailed overview of the disease and a depth understanding of historical and forecasted epidemiology as well as the Pancreatic Cancer Market size and shares analysis for the 7MM (i.e. the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

Pancreatic Cancer Epidemiology

DelveInsight’s Pancreatic Cancer – Epidemiology Forecast 2030 report delivers an in-depth understanding of the disease, historical, and forecasted epidemiology of Pancreatic Cancer in the 7MM (i.e. the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

About DelveInsight

DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end-to-end comprehensive solutions to improve their performance.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: www.delveinsight.com/

Related Articles